Fredun Pharmaceuticals reported a robust start to FY27, with standalone net profit from continuing operations rising 95% year-on-year to ₹13.17 crore for the quarter ended June 30, 2026. The profit surge was driven by a 90% jump in total income to ₹228.25 crore, reflecting strong demand across its diversified portfolio of generics, cosmeceuticals, and nutraceuticals. This performance underscores the company’s operational efficiency and market positioning, offering shareholders confidence in its growth trajectory amid competitive industry dynamics.

The Board of Directors approved the unaudited financial results on August 5, 2026, in compliance with Regulation 47(1)(b) of SEBI Listing Regulations, 2015. The results were published in Active Times and Mumbai Lakshadeep newspapers on August 6, 2026, and filed with BSE Limited under Scrip Code 539730. Consolidated net profit also rose sharply to ₹13.13 crore from ₹6.77 crore in the year-ago quarter, while consolidated revenue mirrored standalone figures at ₹228.25 crore.

Financial Performance Highlights

The company's financial results for Q1FY27 demonstrate significant improvement across key metrics compared to the same period in the previous fiscal year. Revenue from operations, net of GST, stood at ₹227.75 million, up from ₹119.40 million in Q1FY26. Other operating income remained relatively flat at ₹0.49 million. Basic earnings per share (EPS) increased to ₹23.89 from ₹14.33, while diluted EPS stood at ₹22.25.

Operational Efficiency and Margins

The improvement in profitability was not just volume-driven but also reflected better margin retention. Cost of material consumed rose to ₹178.46 million from ₹90.33 million, aligning with the revenue growth trajectory. Other expenses were managed effectively, with employee benefits expenses decreasing slightly to ₹7.12 million from ₹7.63 million. Finance costs stood at ₹8.62 million compared to ₹6.53 million in the year-ago period, while depreciation and amortization expenses increased to ₹3.57 million from ₹1.42 million.

Capital Structure Update

On July 17, 2026, the company allotted 1.10 crore bonus equity shares in a 2:1 ratio to eligible shareholders. This issuance increased the issued and paid-up equity share capital from 55.13 lakh shares to 1.65 crore shares. The consistent public shareholding of 55.43% and stable promoter holding at 44.57% provide a steady ownership backdrop for this growth phase.

What the Numbers Show

The 90% revenue growth significantly outpaced the increase in material costs, indicating strong pricing power or a favorable product mix shift within the pharmaceutical portfolio. With no exceptional items or discontinued operations affecting the bottom line, the profit surge reflects core operational strength. Managing Director Fredun Medhora noted that long-term investments are translating into tangible outcomes, validating the company’s strategy to build a diversified healthcare entity with multiple growth engines.

Fredun Pharmaceuticals Limited has allotted 11,025,380 fully paid-up bonus equity shares in a 2:1 ratio. The allotment was finalized on July 17, 2026, for shareholders on the record date of July 16, 2026. This capital increase follows shareholder approval secured during the Annual General Meeting held on June 30, 2026.

The newly issued shares carry a face value of ₹10 each and rank pari passu with existing equity shares. Holders are entitled to the same dividend and corporate benefits as those declared after the allotment date. The company complied with SEBI Circular No. CIR/CFD/PoD/2024/122 dated September 16, 2024, regarding the deemed date of allotment.

Capital Structure Impact

The bonus issue has significantly expanded the company's equity base. The paid-up share capital increased from ₹5,51,26,900 to ₹16,53,80,700.

Fredun Pharmaceuticals has adjusted the conversion ratio for outstanding warrants. This ensures warrant holders receive the same economic benefit as if conversion had occurred prior to the record date, adhering to the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.